Home/Store/Medicines from India
Rybelsus (Semaglutide) 3 mg, 10 tablets by Novo Nordisk — product pack

Rybelsus (Semaglutide) 3 mg 10 tablets

€116
Oral semaglutide 3 mg, 10 tablets — original Novo Nordisk
In stock
Share this product with your friends
ShareSharePin it
Rybelsus (Semaglutide) 3 mg 10 tablets
Product Details

Rybelsus 3 mg (Semaglutide), 10 tablets

Rybelsus 3 mg is the original oral form of semaglutide — a GLP-1 receptor agonist used on prescription to improve blood sugar control in adults with type 2 diabetes, as an adjunct to diet and exercise. This pack contains one blister card of 10 tablets and is manufactured by Novo Nordisk (India). The 3 mg strength is the standard starting dose for the first 30 days of treatment.

Product overview

  • Trade name: Rybelsus
  • Active ingredient: Semaglutide
  • Strength: 3 mg
  • Dosage form: Tablets for oral use
  • Pack size: 1 blister card × 10 tablets
  • Manufacturer: Novo Nordisk India
  • Country of origin: India
  • Product category: Diabetes / GLP-1 receptor agonists

What Rybelsus is used for

Semaglutide mimics the natural hormone GLP-1: it increases insulin release when blood sugar is high, reduces glucagon, slows gastric emptying and decreases appetite. It is indicated for glycemic control in type 2 diabetes. It is not insulin and is not used for type 1 diabetes or diabetic ketoacidosis.

How to use — important

Rybelsus works only if taken correctly: once daily in the morning on an empty stomach, with a small sip of plain water (no more than 120 ml). After taking it, wait at least 30 minutes before eating, drinking anything else or taking other oral medicines. Swallow the tablet whole — do not split or chew.

Titration schedule

Labeling recommends starting with 3 mg once daily for 30 days, then increasing to 7 mg once daily. If further glycemic control is needed, the dose may be increased to 14 mg once daily after at least another 30 days. The 3 mg dose is a starter dose and is not intended for long-term glycemic control.

Possible side effects

The most common are gastrointestinal: nausea, vomiting, diarrhea, abdominal pain, decreased appetite, constipation — usually milder after the first weeks. Important warnings: pancreatitis (severe persistent abdominal pain), gallbladder problems, dehydration from vomiting/diarrhea, and hypoglycemia when combined with insulin or sulfonylureas. Seek medical help for severe abdominal pain or signs of allergy.

Important precautions

Do not use with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome. Tell your doctor about kidney problems, diabetic eye disease, pregnancy or plans for it (discontinue at least 2 months before a planned pregnancy) and all medicines you take. Not studied in children.

Storage

Store below 25–30°C in the original blister card, protected from moisture, and out of the reach of children. Do not use after the expiry date printed on the pack.

Important notice

The photograph is provided for product identification. Packaging design may vary by batch or market. This page provides general product information and does not replace the package leaflet, diagnosis, prescription or advice from a doctor or pharmacist.

📦 Ask about availability and delivery to your country on WhatsApp

More about this product

Show More
You May Also Like
Rybelsus (Semaglutide) 7 mg, 10 tablets by Novo Nordisk — product pack
Rybelsus (Semaglutide) 7 mg 10 tablets
Rybelsus (Semaglutide) 7 mg 10 tablets
Oral semaglutide 7 mg, 10 tablets — original Novo Nordisk
€122
Rybelsus (Semaglutide) 14 mg, 10 tablets by Novo Nordisk — product pack
Rybelsus (Semaglutide) 14 mg 10 tablets
Rybelsus (Semaglutide) 14 mg 10 tablets
Oral semaglutide 14 mg, 10 tablets — original Novo Nordisk
€121
Pioglitazone Bioton 45 mg 28  tablets
Pioglitazone Bioton 45 mg 28 tablets
Pioglitazone Bioton 45 mg 28 tablets
Hypoglycemic agents
€44
  • My Account
  • Track Orders
  • Shopping Bag
Display prices in:EUR
Skip to main content
APV pharma company
Catalog
Payment and delivery
Contacts
How to place an order
ENRU
Menu
Language:
ENRU
Report Abuse
Powered by Lightspeed